Eli Lilly has the results it was looking for in a second, confirmatory trial of its anti-IL-23p19 antibody mirikizumab in ulcerative colitis as it waits for the outcome of regulatory reviews in the US ...
Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results